Your Insurance Category Determines Which Programs You Can Access
Understanding your insurance situation is the critical first step in navigating GLP-1 affordability. Commercially insured patients (employer plans, ACA marketplace) are typically eligible for manufacturer savings cards. Medicare Part D enrollees are generally excluded from manufacturer savings cards but may access Extra Help (Low Income Subsidy) programs. Medicaid coverage of GLP-1 for obesity varies dramatically by state — some states cover it, many do not. Uninsured patients have the broadest access to patient assistance programs and compounded alternatives. Know your category before applying to any savings program.
Manufacturer Savings Programs
Novo Nordisk and Eli Lilly — the manufacturers of the leading GLP-1 medications — offer savings programs that can reduce costs dramatically for commercially insured and qualifying uninsured patients. These programs are underutilized: millions of eligible patients are paying full price unnecessarily.
Wegovy Savings Card (Novo Nordisk)
The Wegovy Savings Card reduces out-of-pocket costs to as little as $0–$25/month for commercially insured patients whose insurance covers Wegovy — and to a capped monthly amount for patients whose insurance does not cover it. Eligibility requires commercial (non-government) insurance. The card is valid for up to 24 months and is renewable. Enrollment is free through the NovoCare patient services website. Many patients who believe they cannot afford Wegovy are unaware this card can eliminate or dramatically reduce their cost — making enrollment the single most impactful first step for commercially insured GLP-1 candidates.
$0–$25/MonthNovo Nordisk Patient Assistance Program (NNPAP)
The Novo Nordisk Patient Assistance Program provides Ozempic and Wegovy at no cost to uninsured or underinsured patients who meet income eligibility — generally below 400% of the Federal Poverty Level (approximately $60,000 for an individual in 2026). Applications are submitted through the NovoCare website with proof of income and a provider prescription. Processing takes 2–4 weeks. The program also covers patients who have received an insurance denial and are awaiting appeals. NNPAP serves patients in all 50 states and is one of the most impactful programs for low-to-moderate income GLP-1 candidates nationwide.
Free for Qualifying PatientsZepbound Savings Card (Eli Lilly)
Eli Lilly's Zepbound (tirzepatide for weight management) savings card offers a similar structure to the Wegovy card — reducing commercially insured patient costs to as low as $25/month for those with insurance coverage. For uninsured patients, Lilly offers a separate cash-pay program (Zepbound Vials) that provides the medication in single-dose vials at substantially lower prices than the auto-injector pen format. Lilly also operates a patient assistance program (LillyAnswers) for uninsured patients below income thresholds. Enrollment is available through the Lilly Care website with a valid prescription.
Tirzepatide OptionNovoCare Patient Services
NovoCare is Novo Nordisk's centralized patient services hub — providing navigation support for all Novo Nordisk patient savings programs, insurance coverage determination, prior authorization assistance, and appeals support. Patients and providers can call NovoCare directly to determine savings program eligibility, enroll in assistance programs, and get support with insurance navigation. NovoCare coordinators are familiar with the prior authorization requirements across major insurance carriers and can provide documentation templates to support PA submissions. Available by phone and online in all 50 states.
Program NavigationPharmacy Discount Tools
For patients who pay cash for GLP-1 medications — whether uninsured, in a deductible period, or purchasing compounded alternatives — pharmacy discount tools can meaningfully reduce costs at major retail pharmacies nationwide.
GoodRx & RxSaver
GoodRx and RxSaver aggregate pharmacy discount coupons that can reduce cash prices for GLP-1 medications at CVS, Walgreens, Walmart, Kroger, Rite Aid, and thousands of independent pharmacies in all 50 states. While discounts on brand-name Wegovy and Ozempic are less dramatic than for generic medications, GoodRx can reduce cash prices by 10–30% — meaningful savings on medications listing at $1,000+/month. GoodRx is most useful for patients in their insurance deductible period or those who cannot access manufacturer savings cards. Compare prices across nearby pharmacies using the GoodRx app before filling any prescription.
Immediate SavingsMark Cuban Cost Plus Drugs
Mark Cuban's Cost Plus Drugs operates on a transparent pricing model — cost of production plus a fixed markup — and has announced GLP-1 medication offerings at dramatically reduced margins compared to traditional pharmacy pricing. While availability and formulary for GLP-1 medications continues to evolve, Cost Plus Drugs represents a structural alternative to traditional pharmacy distribution that has the potential to reduce costs significantly for cash-paying GLP-1 patients. Check the Cost Plus Drugs website for current GLP-1 availability and pricing compared to your local pharmacy options.
Transparent PricingBlink Health & Optum Rx
Blink Health and Optum Rx (United Health's pharmacy benefit manager operating a retail discount platform) offer additional prescription discount pathways for GLP-1 patients. Blink Health's model allows patients to pay online at a negotiated price and pick up at their local pharmacy. Optum Rx's discount program is particularly valuable for United Healthcare enrollees navigating their pharmacy benefits. Comparing prices across GoodRx, Blink Health, Optum Rx, and Cost Plus Drugs before filling a GLP-1 prescription takes 5 minutes and can identify the lowest available cash price at pharmacies in your area.
Price ComparisonInsurance Navigation & Prior Authorization
Prior authorization (PA) for GLP-1 medications — particularly for the weight management indication — has a 60–70% initial denial rate. But with the right documentation, clinical framing, and appeals strategy, many denials can be overturned. Understanding the PA process is essential for commercially insured GLP-1 patients.
Prior Authorization Process
Prior authorization for GLP-1 medications requires documentation of: BMI meeting the labeled indication threshold (27+ with obesity-related comorbidity or 30+ without); at least one documented comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease for Wegovy); prior documented weight management attempts through diet and exercise; and absence of contraindications. Your prescribing physician must submit the PA request — telehealth platforms with dedicated PA support teams have significantly higher approval rates than solo practitioners unfamiliar with insurer-specific requirements.
Documentation RequiredPA Denial Appeals — Clinical Necessity Letters
When a PA is denied, the appeal process begins with a formal written appeal within 60–180 days of the denial (timelines vary by insurer). The most effective appeals include: a detailed clinical necessity letter from the prescribing physician documenting the patient's BMI, comorbidities, prior weight loss attempts, and the clinical rationale for GLP-1 therapy specifically; peer-reviewed literature supporting GLP-1 efficacy for the patient's indication; and, for diabetes patients, documentation of inadequate glycemic control on alternative therapies. Written appeals overturn approximately 40–50% of initial denials when properly documented.
40–50% Overturn RatePeer-to-Peer Review Requests
A peer-to-peer (P2P) review is a direct conversation between your prescribing physician and the insurance company's medical reviewer — one of the most powerful tools for overturning GLP-1 PA denials. The prescribing physician requests a P2P call (typically within 24–72 hours of denial) and presents the clinical case directly to the insurer's physician reviewer. P2P reviews are particularly effective when the prescribing physician is board-certified in obesity medicine or endocrinology, as peer authority carries significant weight. Many telehealth platforms with dedicated PA support teams arrange P2P reviews as part of their service.
Highly EffectivePatient Advocacy Services for PA Navigation
Dedicated patient advocacy services — including those offered by many GLP-1 telehealth platforms, NovoCare, and independent patient advocacy organizations — provide expert navigation through the PA and appeals process. These services understand insurer-specific criteria, maintain documentation templates proven to succeed at major carriers, and can escalate cases to state insurance commissioners when internal appeals fail. For patients who have received denials on the weight management indication but have concurrent diabetes or cardiovascular disease, reframing the indication (prescribing for the cardiovascular or glycemic indication) is a legal and frequently successful alternative pathway.
Expert NavigationDigital Prescription Management
Managing a long-term GLP-1 prescription — across refills, dose changes, insurance renewals, and potential pharmacy switches — benefits from digital tools that reduce friction and maintain continuity of access.
Prescription Management Platforms
Digital prescription management platforms — including those built into major telehealth portals and standalone tools like PillPack (Amazon Pharmacy), Capsule, and ScriptPro — streamline GLP-1 medication management by automating refill requests, tracking PA renewal deadlines, sending expiration alerts, and facilitating provider communication for dose adjustments. For GLP-1 patients who change insurance mid-treatment or transition between telehealth platforms, these tools help maintain prescription continuity and reduce coverage gaps. Many integrate directly with insurance portals to surface coverage changes and savings opportunities proactively.
Refill AutomationRefill Tracking & Adherence Tools
GLP-1 adherence tracking apps — including Medisafe, Mango Health, and telehealth platform-native dashboards — help patients stay on schedule with weekly injections, track side effects for provider review, and document progress metrics (weight, energy, side effects) that support ongoing PA renewals and clinical documentation. Many insurers require periodic proof of clinical response (typically 5% body weight reduction at 12–16 weeks) to continue covering GLP-1 medications — making systematic tracking data valuable not just for personal awareness but for insurance compliance purposes. Available on iOS and Android in all 50 states.
Insurance ComplianceGLP-1 Savings Programs Available Nationwide
Manufacturer savings programs, GoodRx, and prior authorization navigation services are available to patients in all 50 states. Savings card programs operate at pharmacies nationwide including CVS, Walgreens, Walmart, Kroger, Rite Aid, and independent pharmacies in every zip code. PA navigation services through major telehealth platforms serve every U.S. state, with particular importance in states without Medicaid GLP-1 coverage — including Texas, Florida, Georgia, and others where commercially insured and uninsured patients bear the full cost burden and benefit most from proactive savings program enrollment.